Malaria – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:31 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malaria – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Multiple Ascending Dose Safety, Tolerability and Pharmacokinetics of MK-7602 in Healthy Volunteers for Malaria https://clinicaltrials.eu/trial/multiple-ascending-dose-safety-tolerability-and-pharmacokinetics-of-mk-7602-in-healthy-volunteers-for-malaria/ Fri, 05 Jun 2026 04:02:50 +0000 https://clinicaltrials.eu/trial/multiple-ascending-dose-safety-tolerability-and-pharmacokinetics-of-mk-7602-in-healthy-volunteers-for-malaria/ Malaria is an illness caused by tiny parasites that are spread through mosquito bites and can lead to fever, chills, and flu‑like symptoms. The study drug MK-7602 is given as a hard capsule taken by mouth, and a matching placebo capsule that contains no active medicine is also used for comparison.

The main goal of the trial is to see whether multiple daily doses of the medication are safe and well tolerated in healthy volunteers and to gather early information on its pharmacokinetics, which means how the body absorbs, distributes, and removes the drug. Researchers will watch for any adverse event (side effect) and will measure the amount of drug in the blood, referred to as plasma, at several time points to understand how long the drug stays in the system, its half‑life, and how quickly it is cleared.

Participants will take the assigned capsule once each day for seven days. During this period, short clinic visits will be scheduled to collect blood samples and check for any side effects. After the final dose, additional blood draws will be done to complete the safety checks and the drug‑level measurements, after which participants will be monitored for a short follow‑up period.

]]> Study on the Effectiveness of Atovaquone and Proguanil for Malaria Prevention in Healthy Volunteers https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atovaquone-and-proguanil-for-malaria-prevention-in-healthy-volunteers/ Wed, 29 Apr 2026 15:05:17 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-atovaquone-and-proguanil-for-malaria-prevention-in-healthy-volunteers/ This clinical trial is focused on studying the disease known as malaria, which is caused by a parasite that infects red blood cells. The study will use a treatment called Malarone, which is a combination of two active substances: proguanil hydrochloride and atovaquone. These substances are taken in the form of a film-coated tablet. Additionally, the study involves the use of PfSPZ Challenge (NF54), which is a solution for injection containing the malaria parasite Plasmodium falciparum, strain NF54, sporozoites. This is used to expose participants to malaria in a controlled way.

The purpose of the study is to evaluate how effective a weekly dose of the oral medication atovaquone-proguanil is in preventing malaria in healthy volunteers who have not been exposed to the disease before. Participants will receive either the medication or a placebo and will be exposed to the malaria parasite through an intravenous injection. The study will monitor the participants for a period to see if the medication can prevent the development of malaria.

Throughout the study, participants will be closely observed to ensure their safety and to check for any side effects related to the medication. The main goal is to determine if the medication can protect against malaria by preventing the increase of parasites in the blood. The study will also look at any side effects that occur from the time the medication or placebo is taken until the end of the study. This research aims to provide valuable information on the prevention of malaria using this specific medication regimen.

]]>